Literature DB >> 17620223

Absorption, distribution and excretion of the new thienopyridine agent prasugrel in rats.

K Hagihara1, A Kurihara, K Kawai, M Kazui, M Takahashi, K Kawabata, N A Farid, T Ikeda.   

Abstract

Prasugrel is converted to the pharmacologically active metabolite after oral dosing in vivo. In this study, (14)C-prasugrel or prasugrel was administered to rats at a dose of 5 mg kg(-1). After oral and intravenous dosing, the values of AUC(0-infinity) of total radioactivity were 36.2 and 47.1 microg eqx h ml(-1), respectively. Oral dosing of unlabeled prasugrel showed the second highest AUC(0-8) of the active metabolite of six metabolites analyzed. Quantitative whole body autoradiography showed high radioactivity concentrations in tissues for absorption and excretion at 1 h after oral administration, and were low at 72 h. The excretion of radioactivity in the urine and feces were 20.2% and 78.7%, respectively, after oral dosing. Most radioactivity after oral dosing was excreted in bile (90.1%), which was reabsorbed moderately (62.4%). The results showed that orally administered prasugrel was rapidly and fully absorbed and efficiently converted to the active metabolite with no marked distribution in a particular tissue.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17620223     DOI: 10.1080/00498250701397721

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  4 in total

1.  Legacy of blood: does prasugrel inhibit megakaryocytes and do juvenile platelets inherit this inhibition?

Authors:  Carlos G Santos-Gallego
Journal:  Haematologica       Date:  2015-09       Impact factor: 9.941

Review 2.  Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel.

Authors:  David S Small; Nagy A Farid; Christopher D Payne; Christopher S Konkoy; Joseph A Jakubowski; Kenneth J Winters; Daniel E Salazar
Journal:  Clin Pharmacokinet       Date:  2010-12       Impact factor: 6.447

3.  Gradual increase in thrombogenicity of juvenile platelets formed upon offset of prasugrel medication.

Authors:  Constance C F M J Baaten; Leo F Veenstra; Rick Wetzels; Johanna P van Geffen; Frauke Swieringa; Susanne M de Witt; Yvonne M C Henskens; Harry Crijns; Sven Nylander; J J J van Giezen; Johan W M Heemskerk; Paola E J van der Meijden
Journal:  Haematologica       Date:  2015-06-25       Impact factor: 9.941

4.  Current concepts on antiplatelet therapy: focus on the novel thienopyridine and non-thienopyridine agents.

Authors:  L Testa; G G L Biondi Zoccai; M Valgimigli; R A Latini; S Pizzocri; S Lanotte; M L Laudisa; N Brambilla; M R Ward; G A Figtree; F Bedogni; R Bhindi
Journal:  Adv Hematol       Date:  2010-12-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.